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Background: The relationship between infection with high-risk strains of human papillomavirus (HPV) and cervical
cancer is transforming prevention through HPV vaccination and HPV oncogenic testing. In Ireland, a national
cervical cancer screening programme and HPV vaccination were recently launched; HPV testing is currently being
integrated into the screening programme. Women’s views on the transformation of cervical cancer prevention have
been relatively little investigated.
Methods: Using qualitative focus groups, we determined women’s knowledge, attitudes towards, and acceptability
of cervical cancer screening, HPV oncogenic testing and vaccination of HPV. Fifty nine women, recruited through
primary care in Ireland, participated in ten focus groups. A dynamic topic guide was developed from literature
reviewed. Women were provided with standardised information about HPV infection, HPV testing. Discussion
transcripts were analysed thematically.
Results: The primary themes that emerged regarding HPV infection were: knowledge, emotional response and
societal influences; especially those of healthcare practitioners. Knowledge, logistics, and psychological impact were
the primary themes relating to HPV testing. Women’s attitudes towards HPV testing changed during discussion as
issues were explored, thus demonstrating the complexity of this issue; lack of existing treatment for HPV infection
influenced women’s attitudes, attachment to existing cervical cancer screening also was a significant factor.
Conclusions: Women currently have a strong attachment to cytology and any changes towards HPV primary
testing will need to be managed carefully. To ensure that future cervical cancer prevention strategies will be
acceptable to women, sufficient thought will have to be given to information provision and education. We
identified the importance to women of healthcare practitioners’ opinions regarding HPV. Appropriate and timely
information on HPV will be crucial in order to minimise possible psychological effects women may have.
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Worldwide 530,000 new cervical cancers are diagnosed
annually and there are 275,000 deaths from the disease
[1]. The disease is largely preventable. Until recently the
cornerstone of prevention was screening, using cervical
cytology tests. However, the recent advent of the human* Correspondence: judemcrae@yahoo.com
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ing prevention strategies.
Genital HPV is a common sexually transmitted virus.
Some strains cause genital warts and others, about 15
“high-risk” types; cause abnormal cervical cells that may
eventually progress to cervical cancer. No specific treat-
ment is available and most infections clear themselves [2].
Co-testing (i.e. primary screening using HPV and cy-
tology tests) is now routinely recommended in USA [2].
Other countries are introducing HPV testing in triage of
women with low-grade abnormal cytology (England [3])Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
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McRae et al. BMC Women's Health 2014, 14:64 Page 2 of 7
http://www.biomedcentral.com/1472-6874/14/64and/or in follow-up of women treated for high-grade
abnormal cytology (Scotland [4], Ireland [5,6], and
others).
Two HPV prophylactic vaccines are currently licensed:
Gardasil (Sanofi Pasteur MSD), and Cervarix (GSK Bio-
logicals). Both vaccines target the most prevalent high-
risk HPV strains, 16 and 18. Gardasil also targets HPV
types 6 and 11 (which are linked with genital warts). The
vaccines are given as a course of three injections over
six-months [7]. While it is expected that these vaccines
can prevent around 70% of cervical cancers, it is also
recognised that widespread vaccination will not elimin-
ate the need for some form of screening [8]. Vaccination
programmes are in place in various countries [8], includ-
ing Ireland [9].
Organised cytology-based screening has been effective
in reducing incidence of and mortality from cervical
cancer at the population-level [10,11]. That success, and
the success of future prevention strategies, is predicated
on achieving high levels of uptake among the target
population. High uptake is dependent on women finding
the strategies acceptable, but the effect of incorporating
HPV testing into established screening programmes re-
mains uncertain. Moreover, concerns have been expressed
regarding the potential impact of HPV vaccination on fu-
ture screening participation [8].
Women’s views on the transformation of cervical can-
cer prevention have been relatively little investigated. In
order to inform policy makers and those tasked with ser-
vice delivery, we aimed to explore women’s attitudes,
knowledge and practices with regard to cervical cancer
screening, HPV testing and vaccination, in the face of
such changes. This study was the first in Ireland to exam-
ine women’s opinions on all aspects of cervical cancer pre-
vention, and in particular on all aspects of HPV testing;
HPV testing is in the process of being introduced into the
national cervical cancer screening programme [9].
Methods
The study setting was Ireland, which has a mixed
public-private healthcare system. Organised cervical can-
cer screening commenced in the mid-western area in
2000, and the national programme, CervicalCheck, was
rolled out in September 2008 providing free cytology
tests to women aged 25 to 60 [5]. Prior to this, oppor-
tunistic screening was widespread.
Qualitative focus groups were used to permit in-depth
exploration of women’s views and because interactions
between group members may stimulate emergence of
additional issues. Focus groups were conducted in urban,
mixed and rural areas, with different socio-economic
characteristics, during August 2007– August 2008.
Women were recruited through general practices, primary
care centres and well women centres using passive(posters in clinics) and active advertising (all women at-
tendees during certain periods were given flyers by the
clinic). Participation was open to women aged >17; previ-
ous experience of cervical cancer screening/cytology tests
was not required. In order to ensure maximum diversity,
women of a range of ages, and public and private patients,
were recruited. Groups were organised until conceptual
saturation was reached.
Women interested in participating returned their de-
tails by post to the research team who telephoned them
to gather preliminary socio-demographic information
and arrange a suitable date for the group. Women were
not offered any financial incentive to participate or pay-
ment, but were offered (after the group) reimbursement
for travel or child-minding costs if required.
Groups were held at locally convenient locations
(e.g. general practices, hotels, civic centres). Women com-
pleted a consent form at the outset and anonymity and
confidentiality were discussed. Groups lasted 90–150 mi-
nutes. A trained facilitator (JM) introduced discussion
topics from the topic guide and a co-facilitator noted
group dynamics and non-verbal communications. Each
group discussed cervical cytology tests and cervical cancer
screening, HPV infection, and then either HPV testing or
HPV vaccination, with this topic chosen at random by the
facilitator before the group started.
The topic guide was developed from review of litera-
ture on women’s attitudes, knowledge and awareness of
cervical cancer screening and HPV. While the topic
guide formed the basis of discussions, it was used dy-
namically, and allowed to evolve such that discussions in
one group informed the topic guide for the next group.
This helped to ensure that sufficient depth was reached.
Following discussion on cervical cytology tests and
cervical cancer screening, the facilitator asked whether
group members were aware of HPV and, if so, what they
knew. Groups were then provided with a brief HPV in-
formation sheet (Additional file 1), which was also read
aloud by the facilitator. The group then discussed HPV;
and awareness of the link between sexual activity and
HPV infection was explored explicitly using prompts. In
the discussion on HPV testing, groups were invited to
discuss: what is involved in testing, advantages and dis-
advantages, impact on screening, and psychological im-
pact. Women were presented with three scenarios for
discussion, relating to different potential uses of HPV
testing: (a) as a primary test, (b) for women with mildly
abnormal cytology to help decide if follow-up is needed,
and (c) in women treated for abnormal cytology to help
decide if further treatments or follow-up are required.
At the conclusion of the group each woman received a
€20 shopping voucher to thank them for their time and
participation; women had no prior knowledge of this.
Women were provided with an information pack relating
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or alleviate any concerns, and were advised to contact
their family doctor if they had any specific health
concerns.
Discussions were audio-recorded, transcribed verbatim
and anonymised. The analysis used a thematic approach
[12,13] and was on-going and iterative, such that analysis
of early focus groups informed the content of later
groups to ensure sufficient depth was reached. To help
ensure validity of coding categories and provide analyt-
ical rigour, two experienced qualitative researchers (in-
cluding JM) independently reviewed the first two focus
group transcripts, coded these and, in discussion, agreed
the principal themes. The codes were applied to the rest
of the dataset (by JM), but the code lists were also re-
fined and developed as analysis progressed. Descriptive
accounts of each group were prepared and the methods
of Knodel [14] were used to identify more specific
themes. Each theme was considered in the context of all
of the groups.
Ethical approval was granted by the Irish College of
General Practitioners. This study conforms to the RATS
guidelines for qualitative research.
Results
Participants
Fifty nine women participated in ten focus groups
(Additional file 2). Participants were aged from 17 to
69 years (mean = 42), two-thirds were married or co-
habiting and education levels varied. Six women (10%)
had never had a cervical cytology test. 31% were part
of the public healthcare system.
HPV infection
A few women had heard of HPV infection prior to the
group, generally in relation to colposcopy or HPV vac-
cination, but most had not. Even those who had heard of
HPV had unanswered questions about issues such as the
source of infection, transmission and re-infection. The
different HPV strains and risk factors were unknown by
nearly all women. In general women were more con-
cerned about cytological test results and cervical cancer
than HPV infection.
Three primary themes relating to HPV infection emerged:
knowledge, emotional responses, societal influences
(Additional file 3).
Knowledge
Women often wondered why they had not been told
about or heard of HPV. They were eager to obtain more
information, but were wary that inadequately explained
information could result in negative psychological effects
(e.g. worries, fear). Women expressed conflicting opin-
ions about informing the population at large about thelink between HPV and cervical cancer: some were in
favour of providing comprehensive information and
others were more cautious because this may cause fear.
Some women thought if the relationship between HPV
infection and cervical cancer was given greater promin-
ence, it might encourage women to attend for cytology
tests. Women expressed a feeling of security because of
the high prevalence of HPV. This prevalence made
women reluctant to consider, or label, infection with
HPV a sexually transmitted disease (STD).
Emotional responses
Women often expressed shock on learning of the preva-
lence of HPV infection. They felt their emotional re-
sponse to HPV infection would very much depend on
the context and setting in which they first learned of it.
For example, some women felt that finding out about
HPV and its role in cervical cancer in a colposcopy set-
ting would provoke a more intense reaction than learn-
ing of it through HPV vaccination. The way in which
HPV was explained to them by healthcare practitioners
(HCPs) was seen by women to be very important.
Societal influences
Women considered that the opinions of society about
HPV infection would be an important influence on ac-
ceptability of, and any stigma associated with, having a
HPV infection. They suggested that any potential stigma
could be countered in the way in which HPV infection
is explained (e.g. emphasising high prevalence).
As regards health issues, most women described defer-
ring to trusted sources such as HCPs or the Department
of Health, and thought they would feel this way about
HPV also. These women felt that HCPs did not currently
provide women with enough information about HPV in-
fection. Even women who did not defer responsibility
stated that they would take the opinions of HCPs and
the Department of Health regarding HPV and its role in
cervical cancer prevention into consideration. The atti-
tude of HCPs was viewed as especially important by
women; a positive attitude by a HCP was considered
more likely to mitigate women’s concerns about HPV.
HPV testing
Women tended to perceive that HPV testing was more
personally relevant to them than HPV infection. Early in
the discussions most women felt that they would want
to have a HPV test in addition to a usual cytology test;
this resulted from a desire to “take care” of their bodies
and to know if they had a HPV infection. However over
the course of each discussion, issues such as the preva-
lence of HPV and a lack of treatment caused most of
these women to become less certain about being tested;
by the end of each discussion, most considered that
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sary worry. Strong feelings of reliance on existing cer-
vical screening cytology was found as women discussed
HPV testing. If testing was to be done, women consid-
ered that it would be most acceptable as part of triage
for low-grade abnormal cytology tests, since women
who tested positive would then undergo some manage-
ment/follow-up. Women who declared themselves as
proactive with regard to preventative healthcare were
more likely to be in favour of having HPV tests, and less
likely to change their mind about HPV testing during
the course of discussion.
Three primary themes emerged in relation to HPV
testing: knowledge, logistics, and psychological effect
(Additional file 3).
Knowledge
Almost all women, even those who were aware of HPV
infection and vaccination, lacked any knowledge of
HPV testing. Only one woman stated she was aware of
HPV testing, having learned of it in relation to having
treatment for abnormal cytology.
On learning about the introduction of HPV testing in
other countries, some women questioned whether it was
more reliable than cytology. However, women were con-
fused about what HPV tests involved and whether HPV
testing and cytology tested for the same thing: specifically
women questioned how someone could have a positive re-
sult for one test, and not the other. Some women thought
HPV testing should be offered as a preventative measure
to limit HPV transmission.
Logistics
Women thought that, if a HPV test was to be con-
ducted, it should, for convenience, be carried out at the
same time as a cytological test, and by the same HCP.
They were keen for international guidelines and
methods of best practice to be followed. Issues such as
cost of testing and possible physical discomfort were also
raised.
Psychological effect
Women spoke about fears of testing HPV positive, due
to the possible implications for their health and relation-
ships and fear of the unknown. Women discussed exten-
sively possible feelings of anger and blame within
relationships if a woman tested positive. They expressed
a desire for men to be tested; and commonly described
feelings of anger, or anticipated feeling angry, about how
HPV was contracted. They also expressed worries and
potential embarrassment about the difficulty of talking
to a partner about being HPV tested and/or revealing
HPV status due to the sexually transmittable nature
of HPV.Women described feeling “powerless” at the lack of
treatment of HPV; this then made them call into ques-
tion the purpose and value of testing especially when cy-
tology tests were already available.
Women spoke about the worry that could result from
waiting for HPV test results. Some women considered
that adequate explanation of results would be of para-
mount important in order to minimise negative psy-
chological effects associated with testing positive. In
contrast, others believed that a positive HPV test would
be an encouragement to attend for further screening/
treatment and receiving a negative HPV test would be
reassuring.
Discussion
Women’s trust in cytology
Incorporating HPV testing into cervical cancer screen-
ing, could change women’s perceptions of cervical can-
cer and influence sexual attitudes and behaviours in the
population. This, in turn, may affect screening participa-
tion and its psychological impact. Most leaders in the
area anticipate HPV primary screening will be imple-
mented within a few years [15-17]. One of the main
findings of this study, however, was that women were
concerned with the lack of treatment for HPV infection
and showed a preference for existing cytology. This sug-
gests that changing screening from cytology-based to
HPV-based may face significant obstacles.
While a national cervical cancer screening programme
was not in place in Ireland at the time of this study,
many women had had cytology tests, often on an oppor-
tune basis such as post-childbirth. This seems to have
generated strong feeling of dependence and reliance on
cytology. Studies in other settings have also found that
women trust cytology and are reluctant to replace it. In
an American focus group study [18] nearly all partici-
pants were firmly set against reducing the frequency of
cytology tests. An Australian study [19] found that 85%
of women wanted concurrent cytology and HPV testing.
Cytology screening rates are falling in a number of coun-
tries [20] and further changes to prevention protocols
(such as a move to primary HPV testing) may negatively
impact these.
Role of HCPs and government
The role of HCPs in influencing their patients’ health
screening behaviours is well documented [21,22]. This
study extended these observations into the arena of
HPV. The majority of women deferred responsibility for
health prevention to their HCP and governmental health
departments, suggesting that women’s attitudes and re-
sponses to changes to cervical cancer screening, includ-
ing perhaps the introduction of primary HPV testing,
will be strongly influenced by their relationship with
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be lead and encourage by the government and HCPs. It
is of some concern, therefore, that primary care practi-
tioners (who, in Ireland, conduct the majority of cervical
screening tests) have significant gaps in their knowledge,
and feel considerable uncertainty, about HPV infection,
testing and vaccination [23-25].
Knowledge of HPV infection and HPV testing
In common with studies elsewhere [26-35], in this study
women had many unanswered questions about HPV in-
fection and its association with cervical cancer. Specific-
ally there was confusion over source, treatment and re-
infection, similar to UK findings [36]. One of the most
notable findings was that women’s opinions about HPV
testing altered during the discussion: initial support for
comprehensive testing transformed into favouring much
more limited or reactive HPV testing. Moreover, women
made little connection between having a positive HPV
test result and being at risk of cervical cancer. The im-
plication of these findings is that it may be difficult for
women (with their current levels of knowledge about
HPV) to appreciate why prevention strategies are chan-
ging and to make informed choices about HPV testing
within screening.
Psychological effects of HPV testing
If HPV testing was unacceptable to the general popula-
tion, or caused high levels of distress or anxiety among
those tested, this would have serious implications for the
possible use of HPV testing in routine cervical cancer
screening. In this study, the lack of treatment for those
who test HPV positive was a major concern for women,
who consequently expressed greater confidence in cy-
tology as they knew treatment options are available for
those with abnormal results. This suggests that screen-
ing programmes may face significant challenges around
informing women that they are infected with a high risk
“cancer virus” but not offering explicit treatment. This
has important implications for education and informa-
tion initiatives around new screening protocols.
Other studies have suggested that HPV testing may be
a sensitive and complex issue for women, confounded
by the psychosocial stigmas and distress associated with
contracting a STD and its link to cervical cancer
[37-39]. Similarly, in this study women frequently de-
scribed possible feelings of anxiety, fear, stigmatisation
and concern about their sexual relationships. However
our study also found that the impact of possibly testing
positive varied; for some women understanding that
HPV is a common infection and can potentially clear up
on its own appeared to reduce potential for stigma and
embarrassment. The high prevalence also led some
women to feel secure about testing positive and helpedthem disassociate HPV from other STDs. This suggests,
for HCPs and screening programmes, that emphasizing
how common and “normal” HPV infection is may help
minimise adverse psychological effects of HPV testing.
Our findings also suggest other ways in which messages
about HPV may be best framed. Specifically, moving the
focus towards cervical cancer and away from HPV itself
may be more acceptable to women. Clearly the provision
of adequate and appropriate information for women
about HPV will be vital. This, however, is unlikely to be
a trivial undertaking since, as we and others have shown,
women are likely to vary in their need and desire for in-
formation [40]. Johnson et al. [39] found that associa-
tions between HPV status and anxiety may be explained
by factors other than learning of test results and may
vary by ethnicity and lifestyle factors, highlighting the
need for tailored information.
Strengths & limitations
The major advantage of qualitative focus groups is that,
as well as gathering participants’ views, the interactions
between participants may reveal additional issues. An
example of this was the change in women’s opinions
about HPV testing as discussions progressed; to our
knowledge, this is the first study to identify the evolving
nature of women’s responses to HPV. A major strength
of the study is that it was carried out soon after the
introduction of the HPV vaccination programme and,
therefore, is likely to have captured any impact that this
had on awareness of HPV amongst the population.
Moreover, while these focus groups were conducted
some time ago, their messages and implications remain
timely; only within the past year have several screening
programmes started to introduce HPV testing [2-6].
In recruiting to the focus groups we aimed for max-
imum diversity of women’s opinions and experiences
(e.g. 10% of women never had a smear before, similar to
the national population [6]). This diversity was evident
both in their characteristics (which reflected the national
socio-demographic [41] and % public patients [42]) and
the views they expressed. None of the women in the focus
groups worked directly in health related areas; however, it
is possible that some women volunteering to take part be-
cause they had particular interest in the topic (i.e. cervical
cancer screening). Another limitation is that, as in other
qualitative studies, the relative weight or importance of
themes and subthemes is not always clear.
Conclusions
Despite the changing landscape of cervical cancer pre-
vention, women remain strongly attached to cytology
testing. They have concerns with the lack of treatment
for HPV infection and this impacted on their prefer-
ences on how HPV testing might be accommodated, in
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will play a crucial role in securing women’s support and
compliance with HPV testing. Tailored, appropriate and
timely information regarding HPV will be needed to
minimise adverse psychological effects and ensure that
future cervical cancer prevention strategies continue to
be effective.
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